CAS 1051375-16-6
:Dolutegravir
- (4R,12aS)-N-[(2,4-Difluorophenyl)methyl]-3,4,6,8,12,12a-hexahydro-7-hydroxy-4-methyl-6,8-dioxo-2H-pyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazine-9-carboxamide
- (4R,12aS)-N-[(2,4-Difluorophenyl)methyl]-3,4,6,8,12,12a-hexahydro-7-hydroxy-4-methyl-6,8-dioxo-2H-pyrido[1′,2′:4,5]pyrazino[2,1-b][1,3]oxazine-9-carboxamide
- (4R,9aS)-5-Hydroxy-4-methyl-6,10-dioxo-3,4,6,9,9a,10-hexahydro-2H-1-oxa-4a,8a-diaza-anthracene-7-carboxylic acid 2,4-difluoro-benylamide
- 2H-Pyrido[1′,2′:4,5]pyrazino[2,1-b][1,3]oxazine-9-carboxamide, N-[(2,4-difluorophenyl)methyl]-3,4,6,8,12,12a-hexahydro-7-hydroxy-4-methyl-6,8-dioxo-, (4R,12aS)-
- Dolutegravir free acid
- Gsk 1349572
- Gsk1349572
- S/Gsk1349572
- Soltegravir
- Tivicay
- Dolutegravir
(4R,12aS)-N-(2,4-Difluorobenzyl)-7-Hydroxy-4-Methyl-6,8-Dioxo-3,4,6,8,12,12a-Hexahydro-2H-Pyrido[1',2':4,5]Pyrazino[2,1-b][1,3]Oxazine-9-Carboxamide
CAS:(4R,12aS)-N-(2,4-Difluorobenzyl)-7-Hydroxy-4-Methyl-6,8-Dioxo-3,4,6,8,12,12a-Hexahydro-2H-Pyrido[1',2':4,5]Pyrazino[2,1-b][1,3]Oxazine-9-CarboxamidePurezza:98%Peso molecolare:419.38g/molRef: 54-PC109099
1g156,00€5g380,00€10gPrezzo su richiesta25g966,00€100gPrezzo su richiesta100mg81,00€250mg97,00€Ref: 4Z-D-093002
5mgPrezzo su richiesta10mg2.427,00€25mg4.368,00€50mg7.220,00€100mgPrezzo su richiesta12x1mg6.402,00€Ref: 4Z-D-093045
5mgPrezzo su richiesta10mgPrezzo su richiesta25mgPrezzo su richiesta50mgPrezzo su richiesta100mgPrezzo su richiestaDolutegravir
CAS:Dolutegravir (GSK1349572), HIV integrase inhibitor with IC50 of 2.7 nM, partly effective against some raltegravir-resistant HIV strains.Formula:C20H19F2N3O5Purezza:98.97% - 99.75%Colore e forma:White To Pale Yellow SolidPeso molecolare:419.38Ref: TM-T6198
1mg34,00€5mg71,00€10mg105,00€25mg168,00€50mg222,00€100mg295,00€200mg432,00€1mL*10mM (DMSO)65,00€Dolutegravir
CAS:Applications Dolutegravir is a second generation HIV-1 integrase strand transfer inhibitor. Dolutegravir is currently in Phase III clinical trials for the treatment of HIV infection. Dolutegravir has been shown to potently inhibit HIV replication in cells such as peripheral blood mononuclear cells (PBMCs), MT-4 cells and CIP4 cells infected with a self-inactivating PHIV lentiviral vector.
References Kobayashi, M. et al. Antimicrob Agents Chemother., 55, 813 (2011); Garrido, C. et al.: Antiviral, Res., 90, 164 (2011); Lenz, J.C.C. et al.: Exp. Opin. Invest. Drugs, 20, 537 (2011);Formula:C20H19F2N3O5Colore e forma:White To BeigePeso molecolare:419.38Dolutegravir-d4
CAS:Prodotto controllatoApplications Isotope labelled Dolutegravir is a second generation HIV-1 integrase strand transfer inhibitor. Dolutegravir is currently in Phase III clinical trials for the treatment of HIV infection. Dolutegravir has been shown to potently inhibit HIV replication in cells such as peripheral blood mononuclear cells (PBMCs), MT-4 cells and CIP4 cells infected with a self-inactivating PHIV lentiviral vector.
References Kobayashi, M. et al. Antimicrob Agents Chemother., 55, 813 (2011); Garrido, C. et al.: Antiviral, Res., 90, 164 (2011); Lenz, J.C.C. et al.: Exp. Opin. Invest. Drugs, 20, 537 (2011);Formula:C20H15D4F2N3O5Purezza:>80%Colore e forma:NeatPeso molecolare:423.4Dolutegravir
CAS:Dolutegravir is an HIV-1 integrase inhibitor. Dolutegravir is used in the treatment of HIV-1 infections as it hampers the integration of the viral genome into the host DNA (Katlama, 2012). Active on a wide number of HIV-1 phenotypes, dolutegravir is highly bioavailable with an IC90 of more than 30 hours (Cottrell, 2013).Formula:C20H19F2N3O5Purezza:Min. 98 Area-%Colore e forma:White PowderPeso molecolare:419.40 g/molDolutegravir (0.1 mg/mL in Methanol)
CAS:Formula:C20H19F2N3O5Colore e forma:ColourlessPeso molecolare:419.38





